
ROIV Stock Forecast & Price Target
ROIV Analyst Ratings
Bulls say
Roivant Sciences is attractive fundamentally because its first commercial asset is already validating demand: Lisraya generated $31.0M in net sales in its first five weeks after August approval, far above the $4.0M FactSet consensus, with “hundreds” of paid patients at quarter-end and many hundreds by the call. The company also showed improving operating leverage in 2Q27, reporting $35.1M of total revenue, a non-GAAP loss per share of $0.18 versus $0.41 expected, and $4.2B of cash, cash equivalents and marketable securities, which management believes is enough to reach profitability. Beyond the launch, the pipeline adds multiple shots on goal: mosliciguat’s Phase II PHocus data showed a 56.3% placebo-adjusted PVR reduction and brepocitinib’s broader program includes NIU and dermatomyositis, supporting durable long-term value.
Bears say
Roivant Sciences is weighed down by repeated pipeline disappointments, including the failure of IMVT assets in clinical trials for non-infectious uveitis and cutaneous sarcoidosis, as well as mosliciguat in PH-ILD, which weakens confidence in the company’s ability to convert its development portfolio into durable value. The outlook is further pressured by unanticipated safety issues with batoclimab, IMVT-1402, brepocitinib, and other pipeline assets, alongside litigation setbacks that can raise legal and operational risk and distract management from execution. With unaudited financial statements and additional R&D, regulatory, and commercial setbacks, the company appears exposed to heightened uncertainty across both its clinical pipeline and financial reporting.
This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.
ROIV Analyst Forecast & Price Prediction
Start investing in ROIV
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Roivant Sciences Ltd (ROIV) Forecast
ROIV Analyst Forecast & Price Prediction
Start investing in ROIV
Order type
Buy in
Order amount
Est. shares
0 shares